Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-11-06
2007-11-06
Schultz, J. Douglas (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S004000, C435S007210, C435S007230, C435S007310, C435S007320, C435S320100, C435S325000, C435S368000, C435S455000, C435S471000, C424S093200, C424S093210, C536S023100
Reexamination Certificate
active
09964678
ABSTRACT:
Disclosed are transgenic animals and transfected cell lines expressing a protein associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. Also disclosed is the use of such transgenic animals and transfected cell lines to screen potential drug candidates for treating or preventing Alzheimer's disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. The invention also relates to new antisense oligonucleotides, ribozymes, triplex forming DNA and external guide sequences that can be used to treat or prevent Alzheimer's disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas.
REFERENCES:
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5168053 (1992-12-01), Altman et al.
patent: 5830670 (1998-11-01), de la Monte et al.
patent: 5948634 (1999-09-01), de la Monte et al.
patent: 5948888 (1999-09-01), de la Monte et al.
patent: 6071705 (2000-06-01), Wands et al.
patent: 6245523 (2001-06-01), Altieri
patent: WO89/03849 (1989-05-01), None
patent: WO90/06993 (1990-06-01), None
patent: WO92/07065 (1992-04-01), None
patent: WO94/23756 (1994-10-01), None
patent: WO96/15272 (1996-05-01), None
patent: WO96/40895 (1996-12-01), None
CC Linder, Lab Animal, “The Influence of Genetic Background on Spontaneous and Genetically Engineered Mouse Models of Complex Diseases,” May 2001, vol. 30, No. 5, pp. 34-39.
JM Frangiskakis et al., Cell, “LIM-kinase 1 Hemizygosity Implicated in Impaired Visuospatial Constructive Cognition,” Jul. 1996, vol. 86, pp. 59-69.
T Rulicke et al.,Experimental Society, “Germ line transformation of mammals by pronuclear microinjection,” 2000, 85.6, pp. 589-601.
RM Strojek et al., Genetic Engineering: Principles and Methods, “The Use of Transgenic Animal Techniques for Liverstock Improvement,” 1988, vol. 10, pp. 221-246.
L-M Houdebine, Journal of Biotechnology, “Production of pharmaceutical proteins from transgenic animals,” 1994, 34, pp. 269-287.
LJ Mullins et al., Transgenesis in Nonmurine Species, “Perspectives Species: Molecular Medicine in Genetically Engineered Animals,” Apr. 1996, vol. 97, No. 7, pp. 1557-1560.
JO Bishop, Reprod Nutr Dev. “Chromosomal insertion of foreign DNA,” 1996, 36, pp. 607-618.
IA Polejaeva et al., Theriogenology, “New Advances in Somatic Cell Nuclear Transfer: Application in Transgenesis,” 2000, 53, pp. 117-126.
RJ Wall, Theriogenology, “Trangenic livestock: Progress and Prospects for the Future,” 1996, 45, 57-68.
CD Sigmund, Arterioscler Thromb Vasc Biol., “Viewpoint: Are Studies in Genetically Alered Mice Out of Control?” 2000, 20:1425-1429.
T-L Chiu et al., Folding and Design, “Optimizing energy potentials for success in protein tertiary structure prediction,” May 1998, 3, pp. 223-228.
JT Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” 1994, 14,pp. 491-494.
K Yamada et al., Pharmacology & Therapeutics, “Animal models of Alzheimer's disease and evaluation of anti-dementia drugs,” 2000, 88, pp. 93-113.
Trojanowski et al. Brain Pathology, vol. 9, pp. 733-739, 1999.
de la Monte et al., Journal of Neuropathology an Experimental Neurology, vol. 60, pp. 195-207, 2001.
Mucke et al., Brain Research, vol. 666, 51-167, 1994.
Sandhu, Age, 17, 7-11, 1994.
Malherbe et al., Neurobiology of Aging, 17, 205-214, 1996.
Loring et al., Neurobiology of Aging, 17, 173-182, 1996.
Anderson, W.F., “Human gene therapy,”Nature 392:25-30, Macmillan Journals Ltd. (Apr. 1998).
Bloch, D.B., et al., “Identification and Characterization of a Leukocyte-specific Component of the Nuclear Body,”J. Biol. Chem. 271:29198-29204, The American Society for Biochemistry and Molecular Biology, Inc. (Nov. 1996).
Brinster, R.L., et al., “Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs,”Proc. Natl. Acad. Sci. USA 82:4438-4442, National Academy of Sciences (1985).
Chiu, T.-L. and Goldstein, R.A., “Optimizing energy potentials for success in protein tertiary structure prediction,”Folding and Design 3:223-228, Current Biology Ltd. (May 1998).
de la Monte, S.M., et al., “Enhanced Expression of an Exocrine Pancreatic Protein in Alzheimer's Disease and the Developing Human Brain,”J. Clin. Invest. 86:1004-1013, The American Society for Clinical Investigation, Inc. (1990).
de la Monte, S.M., et al., “Regional and Maturation-associated Expression of Endothel in 2 in Rat Gastrointestinal Tract,”J. Histochem. Cytochem. 43:203-209, The Histochemical Society, Inc. (1995).
de la Monte, S.M., et al., “Aberrant GAP-43 Gene Expression in Alzheimer's Disease,”Am. J. Pathol. 147:934-946, American Society for Investigative Pathology (1995).
de la Monte, S.M., and Bloch, K.D., “Aberrant Expression of the Constitutive Endothelial Nitric Oxide Synthase Gene in Alzheimer Disease,”Mol. Chem. Neuropathol. 30:139-159, Humana Press, Inc. (Jan./Feb. 1997).
Games, D., et al., “Alzheimer-type neuropathology in transgenic mice overexpressing v717F β-amyloid precursor protein,”Nature373:523-527, Macmillan Journals Ltd. (1995).
Gossler, A., et al., “Transgenesis by means of blastocyst-derived embryonic stem cell lines,”Proc. Natl. Acad. Sci. USA 83:9065-9069, National Academy of Science (1986).
Gross, J., et al., “Isolation, Characterization, and Distribution of an Unusual Pancreatic Human Secretory Protein,”J. Clin. Invest. 76:2115-2126, The American Society for Clinical Investigation, Inc. (1985).
The Huntington's Disease Collaborative Research Group, “A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes,”Cell 72:971-983, Cell Press (1993).
Kosaka, K., “Dementia and Neuropathology in Lewy Body Disease,”Adv. Neurol. 60: 456-463, Raven Press, Ltd. (1993).
Lannfelt, L., et al., “Alzheimer's disease: molecular genetics and transgenic animal models,”Behav. Brain Res. 57:207-213, Elsevier Science B.V. (1993).
Marx, J., “Major Setback for Alzheimer's Models,”Science 225:1200-1202, American Association for the Advancement of Science (1992).
Ozturk, M., et al., “Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain,”Proc. Natl. Acad. Sci. USA 86:419-423, National Academy of Sciences (1989).
Pursel, V.G., et al., “Genetic Engineering of Livestock,”Science 244:1281-1288, American Association for the Advancement of Science (1989).
Quon, D., et al., “Formation of β-amyloid protein deposits in brains of transgenic mice,”Nature 352:239-241, Macmillan Journals Ltd. (1991).
Salter, D.W., et al., “Transgenic Chickens: Insertion of Retroviral Genes into the Chicken Germ Line,”Virology 157:236-240, Academic Press, Inc. (1987).
Verma, I.M. and Somia, N., “Gene Therapy- promises, problems and prospects,”Nature 389:239-242, Macmillan Journals Ltd. (Sep. 1997).
de la Monte Suzanne
Wands Jack R
Chong Kimberly
Schultz J. Douglas
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
LandOfFree
Transgenic animals and cell lines for screening drugs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic animals and cell lines for screening drugs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic animals and cell lines for screening drugs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853022